Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February

Core Viewpoint - Rhythm Pharmaceuticals, Inc. is actively engaging in the healthcare sector by participating in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, highlighting its commitment to addressing rare neuroendocrine diseases through its lead asset, setmelanotide [1][2][3]. Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases [3]. - The company's lead product, IMCIVREE® (setmelanotide), is an MC4R agonist approved by the FDA for reducing excess body weight and maintaining weight reduction in patients aged 2 years and older with specific genetic obesity conditions [3][4]. - Setmelanotide has also received authorization from the European Commission and the UK's Medicines & Healthcare Products Regulatory Agency for similar indications [3][5]. Product Indications - In the U.S., setmelanotide is indicated for patients with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or deficiencies in POMC, PCSK1, or LEPR [4]. - In the EU and UK, it is indicated for obesity treatment and hunger control associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1 and LEPR deficiencies [5]. Clinical Development - Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases and is also exploring investigational MC4R agonists LB54640 and RM-718, along with a preclinical suite of small molecules for congenital hyperinsulinism [3]. Safety Information - Common adverse reactions associated with setmelanotide include skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection, with an incidence of 20% or more [12].